EBSCX
Price
$9.43
Change
+$0.02 (+0.21%)
Updated
Jun 3 closing price
Net Assets
2.15B
JDJRX
Price
$9.36
Change
+$0.08 (+0.86%)
Updated
Jun 3 closing price
Net Assets
905.63M
Interact to see
Advertisement

EBSCX vs JDJRX

Header iconEBSCX vs JDJRX Comparison
Open Charts EBSCX vs JDJRXBanner chart's image
EBSCX vs JDJRX Comparison Chart in %
View a ticker or compare two or three
VS
EBSCX vs. JDJRX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBSCX is a Hold and JDJRX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
EBSCX has more cash in the bank: 2.15B vs. JDJRX (906M). EBSCX pays higher dividends than JDJRX: EBSCX (2.54) vs JDJRX (0.39). EBSCX was incepted earlier than JDJRX: EBSCX (12 years) vs JDJRX (7 years). EBSCX (2.85) is less costly to investors than JDJRX (1.26). EBSCX (0.00) and JDJRX (0.00) have comparable annual turnover. EBSCX has a lower initial minimum investment than JDJRX: EBSCX (2500) vs JDJRX (1000000). JDJRX annual gain was more profitable for investors over the last year : 8.38 vs. EBSCX (4.90). EBSCX return over 5 years is better than : 23.93 vs. JDJRX (14.56).
EBSCXJDJRXEBSCX / JDJRX
Total Expense Ratio2.761.25221%
Annual Report Gross Expense Ratio2.851.26226%
Fund Existence12 years7 years-
Gain YTD9.41911.13885%
Front LoadN/AN/A-
Min. Initial Investment250010000000%
Min. Initial Investment IRAN/AN/A-
Net Assets2.15B906M237%
Annual Yield % from dividends2.540.39645%
Returns for 1 year4.908.3859%
Returns for 3 years8.893.79235%
Returns for 5 years23.9314.56164%
Returns for 10 years28.89N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AKTX14.840.21
+1.44%
Akari Therapeutics Plc
UFPI80.28-1.04
-1.28%
UFP Industries
ADSK229.60-7.06
-2.98%
Autodesk
SBSI31.72-1.05
-3.20%
Southside Bancshares Inc
NGEN1.91-0.09
-4.50%
NervGen Pharma Corp.